Warfarina

Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics

Role of pharmacogenomics in the management of traditional and novel oral anticoagulants

Using pharmacogenetics in real time to guide warfarin initiation

Prevalence of CYP2C9 and VKORC1 alleles in the Argentine populations

Prediction or warfarin dose - why when and how

Warfarin pharmacogenetics -a rosing tide for its clinicla value

Pharmacogenetic aspects of coumarinic oral anticoagulant therapies

The future or warfarin pharmacogenetics in under-represented minority groups

An acenocoumarol dosign algorithm using clinical and pharmacogenetic data in Spanish patients

The success of pharmacogenomics in moving genetic association studies from bench to bedside

Clinical application of pharmacogenetic-based Warfarin-dosing algorithm in patients of Han nationality

Stroke genetics-prospects for personalized medicine

Warfarin pharmacogenetics-challenges and opportunities for clinical translation

Efficiency and affectiveness of use acenocoumarol pharmacogenetic dosing algorithm

Warfarin dose prediction in childeren using pharmacometirc bridging

CYP2C9 polymorphism and warfarin dose requirements

Farmacogenetica de Warfarina

The largest prospective warfarin-treated cohort supports genetic forecasting

Role of warfarin pharmacogenetic testing in clinical practice

Pharmacogenetics of warfarin- regulatory scientific and clinical issues

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol

Evaluation of Genetic Factors for Warfarin dose prediction

Cytochrome P450 2C9 and VKORc1 genotypes as determinants of acenocoumarol sensitivity

Current Role of pharmacogenomics in cardiovascular medicine

Clinical applications of pharmacogenomics guided warfarin

Warfarin Genotyping Reduces Hospitalization Rates

The use of mechanistic DM-PK-P modelling to assess the power of pharmacogenetic studies

Prospective Study of Warfarin Dosage Requirements based on CYP2C9 and VKORC1 genotypes